Skip to main content
. 2013 Feb 28;8(2):e57092. doi: 10.1371/journal.pone.0057092

Figure 3. Survival curves for DFS and OS in breast cancer patients according to serum CK19-2G2 levels.

Figure 3

(A) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter disease free survival(P = 0.029) than those with lower levels(<2 mU/mL). (B) Kaplan-Meier survival curve showed that patients with high serum CK19-2G2 levels (≥2 mU/mL) had a significantly shorter overall survival(P = 0.040) than those with lower levels(<2 mU/mL).